ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "infliximab and tocilizumab"

  • Abstract Number: 502 • 2014 ACR/ARHP Annual Meeting

    Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab

    Denis Choquette1, Marie-Pier Payette1, Jean-Pierre Raynauld1, Jean-Pierre Pelletier2, Louis Bessette3, Edith Villeneuve1, Boulos Haraoui1, Isabelle Fortin4, Marie-Anaïs Rémillard5, Diane Sauvageau1 and Louis Coupal1, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 3Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, 4Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 5Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada

    Background/Purpose : Tocilizumab, as an intra-venous agent, has been approved for rheumatoid arthritis (RA) in Canada in April 30th, 2010. It was the sixth approved…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.